Free shipping for orders over €20

Management Team

Ms. Roni Kramer, Founder, Chairman and CEO Kamedis Inc.
Roni Kramer founder of Kamedis Dermatology and chairperson of the company for the last 17 years is serving as Kamedis Inc. CEO since October 2015.
An entrepreneur with a strong attraction to Chinese herbs, and an experienced TCM dermatology practitioner with 10 years of experience in treating skin disorders, Roni is leading the Kamedis launch of products in the USA.
Roni attained an M.Sc. in Traditional Chinese Medicine and Chinese herbology at the American College of Traditional Chinese Medicine (ACTCM) in San Francisco, CA, including an internship at Chengdu University and Hospital in Sichuan, China.

Ms. Hila Shwartszorgen, CFO.                                                                     
Ms. Hila Shwartszorgen joined Kamedis in June 2019. Ms. Shwartszorgen has more than 14 years of experience in leading an effective global economic, financial and accounting system, strategy and business development, production and sales planning and portfolio management. Prior to joining Kamedis, Ms. Shwartszorgen worked for OSEM Nestle. Ms. Shwartszorgen holds a BA in Business Management & Economics from the Hebrew University, and MBA from Ben-Gurion University and is a certified as a Risk Manager.

Dr. Yonit Bomstein, Ph.D., MBA, CTO and Head of R&D
Dr. Yonit Bomstein joined Kamedis in 2010, bringing extensive practical and managerial experience in the biopharmaceutical industry, clinical research, biotechnological and pharmaceutical discovery and development, business development, and operational strategic management.
Dr. Bomstein served as CEO at a clinical-stage biotech company developing an immunomodulating treatment for Premenstrual Syndrome. She previously held a position as VP R&D leading a preclinical program for an anti-melanoma immunotherapeutic drug at a biotechnology company GammaCan.  Prior thereto Dr. Bomstein led a preclinical project supporting clinical trials under FDA at a biopharmaceutical company Proneuron Biotechnologies that is being developed autologous immune cell therapy for severe spinal-cord injuries.
Dr. Bomstein holds a Ph.D. in Immunology from the Weizmann Institute of Science, and an MBA from Tel-Aviv University.



Sold Out

Shopping cart